Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

NPM1 Mutated AML Is Associated With Lower Expression Of Poor Prognostic Markers BAALC, ERG and MN1 In Adult Patients With Acute Myeloid Leukaemia

Poonkuzhali Balasubramanian, Ph.D, Ashok kumar Jayavelu, M.Sc, Ajay Abraham, M.Sc, Savitha Varatharajan, M.Sc, Sreeja Karathedath, M.Sc, Senthamizhselvi Anandan, M.Sc, Vivi Srivastava, MD, Aby Abraham, MD, Auro Viswabandya, MD, Alok Srivastava, MD, Vikram Mathews, MD, DM

Blood (2013) 122 (21): 4945.

https://doi.org/10.1182/blood.V122.21.4945.4945

Published: 2013

Journal Articles

Myeloid Derived Suppressor Cells in Acute Leukemia and Its Association with Conventional Cytogenetic and Molecular Risk Factors

Ansu Abu Alex, MSc, Eric Tartour, Alain Gey, Poonkuzhali Balasubramanian, Ph.D, Vivi Srivastava, MD, Rayaz Ahmed, MD, Aby Abraham, MD, Auro Viswabandya, MD, Biju George, MD, Alok Srivastava, MD, Vikram Mathews

Blood (2012) 120 (21): 1446.

https://doi.org/10.1182/blood.V120.21.1446.1446

Published: 2012

Journal Articles

RNA Expression and Polymorphisms in Imatinib Influx and Efflux Transporters Influence Molecular Response to Imatinib Therapy in Newly Diagnosed Patients with Chronic Myeloid Leukemia.

Poonkuzhali Balasubramanian, Ph.D, Preetha Markose, M.Sc, Senthamizh Selvi Anandhan, M.Sc, Ramkrishna Sahu, M.Sc, Vinodhini Kumaraswamy, B.Sc, Vivi Srivastava, MD, Rayaz Ahmed, MD, Aby Abraham, MD, Biju George, MD, Mammen Chandy, MD, Alok Srivastava, MD, Vikram Mathews

Blood (2012) 120 (21): 2785.

https://doi.org/10.1182/blood.V120.21.2785.2785

Published: 2012

Journal Articles

Final Analysis of a Multi-Center Randomized Controlled Trial (IAPLSG04) to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia

Vikram Mathews, MD, Biju George, MD, Farah Jijina, MD, Cecil Ross, MD, Reena Nair, MD, Shashikant Apte, MD, Geetha Narayanan, MD, Atul Sharma, MD, Kavitha M Lakshmi, MSc, Auro Viswabandya, MD, Ezhilarasi Chendamarai, MSc, Poonkuzhali Balasubramanian, Ph.D, Vivi Srivastava, MD, Mammen Chandy, MD, Alok Srivastava, MD

Blood (2011) 118 (21): 426.

https://doi.org/10.1182/blood.V118.21.426.426

Published: 2011

Journal Articles

Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long Term Follow-up Data.

Vikram Mathews, MD, Biju George, MD, Kavitha M Lakshmi, Auro Viswabandya, MD, Ezhilarasi Chendamarai, Poonkuzhali Balasubramanian, Ramachandran Shaji, Vivi Srivastava, MD, Alok Srivastava, MD, Mammen Chandy, MD

Blood (2009) 114 (22): 846.

https://doi.org/10.1182/blood.V114.22.846.846

Published: 2009

Journal Articles

Single Agent Arsenic Trioxide Regimen for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Initial Results of a Multicenter Randomized Controlled Study From India to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy (IAPLSG04).

Vikram Mathews, MD, Biju George, MD, Farah Jijina, MD, Cecil Ross, MD, Reena Nair, MD, Shashikant Apte, MD, Geetha Narayanan, MD, Atul Sharma, MD, Kavitha M Lakshmi, Auro Viswabandya, MD, Ezhilarasi Chendamarai, Poonkuzhali Balasubramanian, Vivi Srivastava, MD, Alok Srivastava, MD, Mammen Chandy, MD

Blood (2009) 114 (22): 2082.

https://doi.org/10.1182/blood.V114.22.2082.2082

Published: 2009

Journal Articles

Increased ABCG2 Expression Could Be Responsible for Resistance to Imatinib Mesylate in Patients with Chronic Myeloid Leukemia Who Do Not Have Mutations in BCR-ABL Kinase Domain

Poonkuzhali Balasubramanian, Preetha Markose, Ezhilarasi Chendamarai, Vikram Mathews, MD, Vivi Srivastava, Shaji R Velayudhan, Kavitha M Lakshmi, Auro Viswabandhya, Biju George, Alok Srivastava, Mammen Chandy

Blood (2008) 112 (11): 5026.

https://doi.org/10.1182/blood.V112.11.5026.5026

Published: 2008

NARROW

NPM1 Mutated AML Is Associated With Lower Expression Of Poor Prognostic Markers BAALC, ERG and MN1 In Adult Patients With Acute Myeloid Leukaemia

Myeloid Derived Suppressor Cells in Acute Leukemia and Its Association with Conventional Cytogenetic and Molecular Risk Factors

RNA Expression and Polymorphisms in Imatinib Influx and Efflux Transporters Influence Molecular Response to Imatinib Therapy in Newly Diagnosed Patients with Chronic Myeloid Leukemia.

Final Analysis of a Multi-Center Randomized Controlled Trial (IAPLSG04) to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia

Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long Term Follow-up Data.

Single Agent Arsenic Trioxide Regimen for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Initial Results of a Multicenter Randomized Controlled Study From India to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy (IAPLSG04).

Increased ABCG2 Expression Could Be Responsible for Resistance to Imatinib Mesylate in Patients with Chronic Myeloid Leukemia Who Do Not Have Mutations in BCR-ABL Kinase Domain

Email alerts

ASH Publications

American Society of Hematology

NPM1 Mutated AML Is Associated With Lower Expression Of Poor Prognostic Markers BAALC, ERG and MN1 In Adult Patients With Acute Myeloid Leukaemia

Myeloid Derived Suppressor Cells in Acute Leukemia and Its Association with Conventional Cytogenetic and Molecular Risk Factors

RNA Expression and Polymorphisms in Imatinib Influx and Efflux Transporters Influence Molecular Response to Imatinib Therapy in Newly Diagnosed Patients with Chronic Myeloid Leukemia.

Final Analysis of a Multi-Center Randomized Controlled Trial (IAPLSG04) to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia

Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long Term Follow-up Data.

Single Agent Arsenic Trioxide Regimen for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Initial Results of a Multicenter Randomized Controlled Study From India to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy (IAPLSG04).

Increased ABCG2 Expression Could Be Responsible for Resistance to Imatinib Mesylate in Patients with Chronic Myeloid Leukemia Who Do Not Have Mutations in BCR-ABL Kinase Domain

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only